Yonsei Med J.  2023 Mar;64(3):175-180. 10.3349/ymj.2022.0287.

Do Statins Counteract the Effect of Antidiabetic Drugs? Results of the SCEAD Study

Affiliations
  • 1Department of Internal Medicine, Kartal Research and Education Hospital, Istanbul , Turkey
  • 2Department of Cardiovascular Risk, Salamanca University, Salamanca, Spain
  • 3Department of Pharmacology, Milano-Bicocca University, Milan, Italy
  • 4Department of Cardiology, Medical Park Hospital, Izmir University, Izmir, Turkey
  • 5Department of Cardiology, Denizli State Hospital, Denizli, Turkey
  • 6Department of Internal Medicine, Bayrampasa State Hospital, Bayrampasa, Turkey
  • 7Department of Medical Pharmacology, University Cerrahpasa, Istanbul, Turkey
  • 8Department of Nephrology, Bahcesehir University, Istanbul, Turkey
  • 9Department of Nephrology, University Hospital of Badajoz, Badajoz, Spain
  • 10Medical Clinics, Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy

Abstract

Purpose
Diabetes and dyslipidemia are leading causes of mortality and morbidity. According to international guidelines, statins are the cornerstone of treatment in patients with diabetes and/or dyslipidemia. However, statins and antidiabetic agents have opposite pharmacological effects, because statins, particularly atorvastatin and rosuvastatin, impair glucose homeostasis, increasing the risk of new-onset diabetes, whereas antidiabetic drugs improve glycemic homeostasis. The aim of this study was to investigate the effect of atorvastatin, rosuvastatin, and pitavastatin on glucose homeostasis in patients with type 2 diabetes mellitus (T2DM) and dyslipidemia during stable treatment with hypoglycemic drugs.
Materials and Methods
The study was conducted as a pilot, prospective, randomized, open label, parallel group with blindedendpoints (PROBE) study. Of 180 recruited patients with T2DM and dyslipidemia, 131 were randomized to atorvastatin (n=44), rosuvastatin (n=45), and pitavastatin (n=42) and treated for 6 months.
Results
Fasting plasma glucose (FPG) marginally decreased in patients assigned to atorvastatin (-3.5 mg/dL, p=0.42) and rosuvastatin (-6.5 mg/dL, p=0.17), while it decreased much more in patients treated with pitavastatin (-19.0 mg /dL, p<0.001). Mean glycated hemoglobin A1c (HbA1c ) values remained unchanged during treatment with atorvastatin (-0.10%, p=0.53) and rosuvastatin (0.20%, p=0.40), but were significantly reduced with pitavastatin (-0.75%, p=0.01). Atorvastatin, rosuvastatin, and pitavastatin significantly lowered (p<0.001) plasma levels of total cholesterol, low-density lipoprotein-cholesterol, and triglycerides, while highdensity lipoprotein-cholesterol (HDL-C) levels increased significantly (p=0.04) only in the pitavastatin group.
Conclusion
The results of the present study suggest that pitavastatin affects FPG and HbA1c less than atorvastatin and rosuvastatin in patients with T2DM and concomitant dyslipidemia. Lipid-lowering efficacies were not significantly different among the three statins, with the exception of HDL-C, which increased significantly with pitavastatin. Although the pharmacological mechanism of pitavastatin on glucose homeostasis in patients with T2DM during stable antidiabetic therapy is not known, it can be assumed that pitavastatin has less drug interaction with hypoglycemic agents or that it increases plasma levels of adiponectin.

Keyword

Type 2 diabetes; fasting plasma glucose; glycated hemoglobin A1c; atorvastatin; rosuvastatin; pitavastatin
Full Text Links
  • YMJ
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr